This suggests that ER modulators such as tamoxifen, acting via ERα and ERβ networks to induce a cytotoxic response, may have a role in the clinical treatment of patients with oesophageal adenocarcinoma. The gene discussed is ESR2; the disease is esophageal adenocarcinoma.